- Posted August 12, 2014
- Tweet This | Share on Facebook
Pfizer to pay $35 million to settle drug marketing case
WASHINGTON (AP) - Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.
The states' attorneys general said last week that Wyeth, which Pfizer bought in 2009, trained sales representatives to encourage doctors to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.
Rapamune was approved in 1999 for use in kidney transplant patients. Promoting drugs for uses not cleared by the Food and Drug Administration is illegal.
Pfizer agreed to pay nearly $491 million in July 2013 to resolve a similar investigation by the Department of Justice.
New York-based Pfizer said in a statement that the alleged activity occurred before it acquired Wyeth. The company did not admit any wrongdoing or liability as part of the settlement.
Published: Tue, Aug 12, 2014
headlines Oakland County
- Annual Dinner & Meeting
- FORCE Team arrests six in prolific auto theft ring
- Michigan allocates $12 million to support community-based organizations in advancing environmental and climate justice
- Oakland County and SMART launch pilot program providing free transit for veterans and dependents
- Supreme Court sides with the Consumer Financial Protection Bureau
headlines National
- More lawyers—and clients—want to learn about sustainable development practices
- Top artificial intelligence insurance tips for lawyers
- Lawyer charged with illegally transmitting Michigan data after 2020 election
- Viral video shows former Rikers Island inmate as she learns she passed bar exam on first try
- How Sullivan & Cromwell is scrutinizing potential new hires after campus protests
- No separate hearing required when police seize cars loaned to drivers accused of drug crimes, SCOTUS rules